CytomX Therapeutics (NASDAQ:CTMX) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:15 PM.
Here’s what investors need to know about the announcement.
Earnings
CytomX Therapeutics beat estimated earnings by 54.55%, reporting an EPS of $-0.05 versus an estimate of $-0.11.
Revenue was up $6.36 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.18 which was followed by a 15.08% drop in the share price the next day.
Here’s a look at CytomX Therapeutics’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.24 | -0.31 | -0.36 | -0.36 |
| EPS Actual | -0.42 | -0.35 | -0.37 | -0.37 |
| Revenue Estimate | 17.85M | 17.94M | 17.90M | 20.66M |
| Revenue Actual | 946K | 16.91M | 18.16M | 17.14M |
To track all earnings releases for CytomX Therapeutics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
